Stem Cell Transplant in Patients With Severe Sickle Cell... | NCT03421756

Status Module

Label	Type	Description	Intervention Names
Non Myeloablative regimen (Alemtuzumab)	Experimental	Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.	Drug: Alemtuzumab Radiation: Total Body Irradiation Drug: Sirolimus

Name	Type	Description	Arm Group Labels	Other Names
Alemtuzumab	Drug	Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Treatment Success	Evaluating reversal of Hb S % to that of the donor's phenotype, in recipients of HLA matched-sibling peripheral blood - hematopoietic stem cell transplantation (HSCT) with NMA conditioning regimen. Testing for treatment success will include Hb Electrophoresis. Recipients with donors AA should have nearly 0% Hb S. Recipients with donors AS should have similar Hb S % (approximately < 60%) as the donor. The proportion of patients experiencing treatment success, will be calculated with a 90% exact confidence interval.	up to 1 year after HSCT

Secondary Outcomes

Measure	Description	Time Frame
Engraftment	To estimate the probability of engraftment, using absolute neutrophil count and platelets along with chimerism analysis after HSCT. This will by evaluated by: 1) Time to ANC of >500/uL on the first of three consecutive days. 2) Time to platelet count >50,000/µL for 3 days without transfusion. 3) Peripheral blood chimerism analysis of whole blood and CD3-lineage will be performed on or around day +30, +90, +180, and +360. 4) Additional peripheral blood chimerism studies may be performed as clinically indicated. The statistical analysis plan will be calculated with a 90% exact confidence interval.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Patient selection
1. Age > 18 years
2. Patients with Hb SS, Hb SC, Hb Sβ0 genotype
3. Presence of at least 1 of the following manifestations:
  1. History of clinically significant neurologic event defined as stroke or any neurological deficit lasting > 24 hours.
  2. History of two or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures
  3. Three or more pain crises per year in the 2-year period preceding referral (required intravenous pain management in the outpatient or inpatient hospital setting).
    
    This may include painful episodes related to priapism, osteonecrosis or any sickle-related complication.
  4. An echocardiographic finding of the tricuspid valve regurgitant jet (TRJ) velocity ≥ 2.7 m/sec.
  5. History of osteonecrosis or avascular necrosis of ≥ 2 joints
  6. Administration of regular RBC transfusion therapy, defined as receiving 8 or more transfusions per year for > 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
  7. History of RBC allo-immunization but without detectable allo-antibodies.
  8. Evidence of sickle hepatopathy or iron overload in patients who received ≥ 8 packed RBC transfusions for ≥ 1 year or have received ≥ 20 cumulative packed RBC transfusions. These patients will undergo MRI of the liver to estimate liver iron content.
  9. Patients with hepatic iron content of ≤ 7 mg Fe/ gm of liver will be included ii. Patients with hepatic iron content of ≥ 7 mg Fe/ gm of liver will undergo biopsy to look for absence of histological findings suggestive of cirrhosis, fibrosis and active hepatitis
  h. Sickle nephropathy defined as Cr ≥ 1.5 times the ULN or biopsy proven i.Reversible SCD complication not ameliorated by hydroxyurea: i.Two or more vaso-occlusive crises requiring hospitalizations ii. Any episode of ACS while on hydroxyurea
4. Adequate physical function as measured by all of the following:
  1. Karnofsky performance score > or equal to 70
  2. Cardiac function: Left ventricular ejection fraction (LVEF) > 40%; or LV shortening fraction > 26% by cardiac echocardiogram or by MUGA scan.
  3. Pulmonary function: Pulse oximetry with a baseline O2 saturation of > 85%, DLCO > 40% (corrected for hemoglobin).
  4. Renal function: Serum creatinine ≤ 1.5 x the upper limit of normal for age as per local laboratory and 24 hour urine creatinine clearance >70 mL/min/1.73 m2; or GFR > 70 mL/min/1.73 m2 by radionuclide GFR unless reason for transplant is sickle nephropathy
  5. Hepatic function:
  i. Serum conjugated (direct) bilirubin < 2x upper limit of normal for age as per local laboratory; ii. ALT and AST < 5 times upper limit of normal. iii. Patients with hyperbilirubinemia because of hyper hemolysis, or who experience a sudden, profound change in the serum hemoglobin after a RBC transfusion are not excluded.
5. The HLA matched related donor must be willing to donate and must meet our institutional guidelines to donate peripheral blood stem cells
6. Absence of donor specific HLA antibodies.
7. Absence of clinical or radiographic evidence of neurologic event within 6 months prior to proceeding with transplantation.
  1. Cerebral MRI/MRA within 6 months prior to initiation of transplant conditioning.
  2. If patient has a neurologic event such as stroke or transient ischemic attack during recruitment process, patient will be deferred for 6 months before reconsideration.

Donor selection

Siblings who are ≥18 years and capable and willing to donate PBSC
Sibling donors are HLA-matched. HLA-A, B, C, and DRB1 match based on high-resolution typing
All sibling donors MUST meet institutional criteria for donation.
Donors with sickle cell trait (Hb AS) are permitted.
Donors with ABO minor incompatibility are permitted

Exclusion Criteria:

Patient selection

Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.
Seropositivity for HIV.
Previous stem cell transplantation.
Participation in a clinical trial in which the patient received an investigational drug or device
A history of substance abuse as defined by version IV of the Diagnostic & Statistical Manual of Mental Disorders (DSM IV).
Demonstrated lack of compliance with prior medical care as determined by referring physician.
Pregnant or breast-feeding females.
Unwillingness to use approved contraception method from time of conditioning regimen and 4 months after discontinuation of all immunosuppressive medications.

Donor selection A. Inclusion Criteria

Siblings who are ≥18 years and capable and willing to donate PBSC
Sibling donors are HLA-matched. HLA-A, B, C, and DRB1 match based on high-resolution typing
All sibling donors MUST meet institutional criteria for donation.
Donors with sickle cell trait (Hb AS) are permitted.
Donors with ABO minor incompatibility are permitted

B. Exclusion Criteria

Donors with hemoglobinopathies: Hb SS, Hb SC, Hb Sβ0 and all other unstable hemoglobins
Presence of anti-donor HLA antibodies in the recipient
Donors with major ABO incompatibility are permitted
Donors who are HIV-1, HIV-2, HTLV-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection

ID	Term
D000745	Anemia, Hemolytic, Congenital
D000743	Anemia, Hemolytic
D000740	Anemia
D006402	Hematologic Diseases

ID	Term
D000074323	Alemtuzumab
D014916	Whole-Body Irradiation
D020123	Sirolimus

ID	Term
D061067	Antibodies, Monoclonal, Humanized
D000911	Antibodies, Monoclonal
D000906	Antibodies
D007136	Immunoglobulins